



Port Said University

Faculty of Science

Chemistry & Biochemistry Department



Biochemical evaluation of
(hydroxy-2-oxo-N-(p-tolyl)-2H-chromene-3-carboxamide)
as antitumor

Supervised by:

Dr/ Mohammed Samy Gharib

Presented by:

Esraa Ali Abdo Ibrahim Barghout

Presented to

Port Said University

Faculty of Science

Biochemistry Department

4th level

2016

Acknowledgments

First of all, limitless gratitude to **God**, most merciful, who blesses my effort, shows me the way and enables me to present this work in an acceptable style.

Special thanks to my supervisor *Prof. Dr. Ibrahim MohyEldin (Prof. of organic chemistry, Faculty of science, Port Said University)* for giving me the honor of working under his supervision, supplying the equipment and facilities required to accomplish this work.

Also I would like to express my thanks to *Dr. Mohamed Elbehery (Assistant lecturer of Biochemistry, Faculty of science, Port Said University)* for his support, exertion continuous encouragement and advices during the work.

Table of content

Chapter1:-

I. Introduction.....	1
I.1.Cancer.....	2
I.1.1.Development of Cancer.....	3
I.1.2.Genetics of Cancer.....	5
I.2.Tumers.....	9
I.2.1.Benign.....	9
I.2.2.Malignant.....	9
I.2.3.Tumer Marker.....	12
I.3.Some Causes of Cancer.....	13
I.3.1.Environmental Factors.....	13
I.3.2.Viruses and Cancer.....	14
I.4.Some general signs and symptoms of Cancer.....	15
I.5.Selected Cancers.....	20
I.6.Cancer Therapy.....	29
I.6.1.Surgery.....	29
I.6.2.Chemotherapy.....	30
I.6.3.Radiation therapy.....	32
I.7.Ehrlich ascites carcinoma.....	33
I.8.Biological activity of coumarin derivatives.....	38

Chapter 2:-

II. Material & Method.....	43
II.1. materials.....	43
II.2. Methods.....	45
II.2.1. Properties of 7-hydroxy-N-(4-methylphenyl)-2-oxo-2H-chromene-3-carboxamide.....	48
II.2.2. Properties of 7-hydroxy-N-(4-methylphenyl)-2-oxo-2H-chromene-3-carboxamide.....	50
II.2.3. Properties of 7-hydroxy-N-(4-methylphenyl)-2-oxo-2H-chromene-3-carboxamide.....	52
II.2.4. In vitro studies.....	54
II.2.4.1. Determination of potential cytotoxicity of synthetic Compound on human cancer cell line.....	56
II.2.5. In vivo studies.....	58
II.2.5.1. Toxicity studies.....	58

Chapter 3:-

III. Result & Discussion.....	60
III.1. In vitro studies.....	60
III.2. In vivo studies.....	65
III.3. Discussion.....	65

Chapter 4:-

IV. References.....	66
----------------------------	-----------

List of figure

Fig. 1: Cancer cell division.....	1
Fig. 2: Process of development.....	4
Fig. 3: Oncogene.....	6
Fig. 4: Tumor Suppressor Genes.....	7
Fig. 5: DNA repair.....	8
Fig. 6: Malignant cancer.....	10
Fig. 7: Benign & malignant tumors.....	11
Fig. 8: Tumors markers.....	13
Fig. 9: Risk and protective factors.....	15
Fig. 10: Breast cancer.....	21
Fig. 11: liver cancer.....	22
Fig. 12: colon and rectum cancer.....	23
Fig. 13: kidney cancer.....	24
Fig.14: Leukemia.....	25
Fig.15: Lymphoma.....	26
Fig.16: Skin cancer.....	28
Fig. 17: Ehrlich ascites carcinoma.....	37
Fig. 18: Application of Coumarins.....	38
Fig. 19: Ehrlich ascites carcinoma (EAC).....	44
Fig. 20: Trypan blue staining.....	54
Fig. 21: Haemocytometer.....	55

Fig. 22: Injected doses.....	58
Fig. 23: Hemocytometer.....	59
Fig. 24: Evaluation of cytotoxicity of prepared compound against cell line MCF-7.....	60
Fig. 25: Evaluation of cytotoxicity of prepared compound against cell line HEPG-2.....	61
Fig. 26: Evaluation of cytoyoxicity of prepared compound against cell line HCT.....	62
Fig. 27: Evaluation of cytotoxicity of prepared compound against cell linePC-3.....	63

List of table

Table 1: characteristic of benign and malignant tumors.....	11
Table 2: Serum tumor marker.....	12
Table 3: Evaluation of cytotoxicity of prepared compound against cell line MCF-7.....	60
Table 4: Evaluation of cytotoxicity of prepared compound against cell line HEPG-2.....	61
Table 5: Evaluation of cytoyoxicity of prepared compound against cell line HCT.....	62
Table 6: Evaluation of cytotoxicity of prepared compound against cell linePC-3.....	63

Abbreviation

KSHV	Kaposi's sarcoma herpes virus
ALL	Acute Lymphocytic Leukemia
CLL	Chronic Lymphocytic Leukemia
AML	Acute myeloid Leukemia
CML	Chronic myeloid Leukemia
NHL	Non-Hodgkin's Lymphoma
NMSC	No melanoma skin cancer
IA	Intra-arterial
IP	Intraperitoneal
IV	Intravenous
H-2	Histocompatibility antigen
EAC	Ehrlich ascites
S.C.	Subcutaneous injection
RNA	Ribose nucleic acid
ATP	Adenosine Tri-phosphate
GSH	Glutathione
NK	Natural killer cells
EACF	Ehrlich ascites carcinoma factor
HIV	Human immunodeficiency virus
HSV	Herpes simplex virus
Hi-Media	Hinton agar media
DMSO	Dimethyl sulfoxide
S.aureus	Staphylococcus aureus
EDTA	Ethylene diamine tetra acetic acid
RPMI-1640	Roswell park memorial institute
HCT	Human colon cancer cell line
MCF-7	Human breast cancer cell line
HepG-2	Human hepatocellular cancer cell line
IR spectra	Infra-red spectra
NMR spectra	Nuclear magnetic resonance
MHZ	Megahertz
TMS	Transcranial magnetic stimulation
MS	Mass spectra
m.p	Melting point
ppm	Parts per million
FBS	Fetal bovine serum
SRB	Sulphorhodamine-B
TCA	Trichloroacetic
O.D	Optical density = Survival fraction

ELISA	Enzyme linked immune sorbent assay
LD	Lethal dose
IC	Inhibitory concentration